Immunovia invitation to a teleconference on 24 August 2016

Immunovia invites you to a teleconference in connection with the publishing of
the first half-year report for 2016. The conference call will take place at 10
a.m. on 24 August and the results will be published at around 8.30 a.m. the same
day
Immunovia invites you to a teleconference in connection with the publishing of
the first half-year’s results for 2016. The conference call, which is expected
to last for a maximum one hour, will be held in Swedish. After a presentation of
the company by CEO Mats Grahn, you will have the opportunity to ask questions.
Please dial in a few minutes before the conference call begins.
Date: August 24, 2016
Time: 10:00 (CET)
Phone numbers:
SE: +46 8 566 426 62
CH: +41 225 675 548
DE: +49 692 222 290 46
UK: +44 203 008 98 04
On Immunovias website under Investors / Financial Reports
(http://immunovia.com/investors/financial-reports/) there will be an MP3 file
for anyone who wants to listen to the conference afterwards. The file will be
available within 2 hours after the conference has ended.
Half-year results are expected to be published at 08.30 a.m. (CET) on 24 August.
For questions and interview appointments:
ir@immunovia.com

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of
Immunotechnology at Lund University and CREATE Health, the Center for
Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to
decipher the wealth of information in blood and translate it into clinically
useful tools to diagnose complex diseases such as cancer, earlier and more
accurately than previously possible. Immunovia´s core technology platform,
IMMray™, is based on antibody biomarker microarray analysis. The company is now
performing clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early diagnosis of
pancreatic cancer.  In the beginning of 2016, the company started a program
focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The
first test from this program, IMMray™ SLE-d, is a biomarker signature derived
for differential diagnosis of lupus, now undergoing evaluation and validation.
(Source: www.immunovia.com)

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and
Wildeco is the company’s Certified Adviser. For more information, please
visit www.immunovia.com.

###